A clearstate report

Next-generation sequencing (NGS) in cancer biomarker testing: testing trends in Europe labs

Europe’s cancer burden is increasing, with more patients undergoing biomarker testing in order to access more targeted and effective therapies.

Economist Intelligence Clearstate expects the number of patients undergoing routine molecular testing for cancer biomarkers tracked by IVD Gateway to grow at an average annual rate between 6.2 to 19.2% in EU5 countries from 2020 to 2025.

While PCR-based molecular diagnostics (MDx) is an essential component of cancer care, molecular testing technologies such as next-generation sequencing (NGS) that supports rapid, high-throughput, highly sensitive, affordable testing, are becoming of increasing importance as the burden of cancer in Europe rises.

This paper explores the state of NGS testing for cancer biomarkers in Europe based on our study of EU5 clinical laboratories.

Download free report

Download free report

Simply fill in the form below to access this free report.

Clearstate newsletter

The latest trends and insights into the IVD and Surgical sectors, from our specialists and analysts, delivered directly to your inbox. Sign up to Clearstate's newsletter today.